Drug intelligence / Profile preview

AD07030

Development stage: Phase 2
Lead developer: Advagene
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

AD07030 is a nasal spray seasonal influenza vaccine under development. It is formulated as a trivalent inactivated split virion influenza vaccine combined with a proprietary mucosal adjuvant (AD07010). This combination is designed to enhance both systemic (serum) and mucosal immune responses for the prevention of seasonal influenza virus infection. Phase II clinical trial data show that AD07030 increases both blood and mucosal immune responses while demonstrating a favorable safety and tolerability profile[5][7].

Other names: Nasal Spray Seasonal Flu VaccineLTh(αK) adjuvanted intranasal influenza vaccinelive attenuated influenza vaccine-Advagene Biopharma-Influenza antigens-Intranasal vaccine-mucosal adjuvant (LTh(αK) platform)-intranasal-Seasonal influenza

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on AD07030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD07030.

Explore the full profile